| EARNINGS / LOSS PER SHARE |
| (10) |
EARNINGS / LOSS
PER SHARE |
The
factors used in the basic and diluted earnings / loss per share computation follow:
SCHEDULE
OF EARNINGS PER SHARE
| | |
March
31, 2026 | | |
March
31, 2025 | |
| | |
Three
Months Ended | |
| | |
March
31, 2026 | | |
March
31, 2025 | |
| | |
| | |
| |
| Net loss | |
$ | (4,545 | ) | |
$ | (4,114 | ) |
| | |
| | | |
| | |
| Weighted average common shares outstanding | |
| 44,264,315 | | |
| 42,068,550 | |
| | |
| | | |
| | |
| Earnings (loss) per common share | |
$ | (0.10 | ) | |
$ | (0.10 | ) |
There
were 4,013,319 and 3,558,718 stock options and warrants outstanding as of March 31, 2026 and March 31, 2025. All outstanding options
and warrants are anti-dilutive due to the net loss position of the Company.
|
| (16) |
EARNINGS
/ LOSS PER SHARE |
The
factors used in the basic and diluted earnings / loss per share computation follow:
SCHEDULE
OF EARNINGS PER SHARE
| | |
2025 | | |
2024 | |
| | |
| | |
Restated | |
| Basic
and diluted: | |
| | | |
| | |
| Net
loss | |
$ | (14,842 | ) | |
$ | (14,486 | ) |
| | |
| | | |
| | |
| Weighted
average common shares outstanding | |
| 42,705,299 | | |
| 40,365,075 | |
| | |
| | | |
| | |
| Earnings
(loss) per common share | |
$ | (0.35 | ) | |
$ | (0.36 | ) |
There
were 3,952,802 and 3,491,718 stock options and warrants that were anti-dilutive for the years ended December 31, 2025 and December 31,
2024, respectively, due to the net loss position of the Company.
|